Durham, North Carolina
Cancer clinical trials in Durham, NC
182 cancer studies are recruiting participants at sites in Durham as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Durham at a glance
- 182 studies are recruiting at a site in Durham.
- By phase: Phase 1 (34), Phase 1/2 (29), Phase 2 (28), Phase 2/3 (7), Phase 3 (48), Phase 4 (3), No phase (18), Observational (15). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (106), university, hospital or other (59), government (17).
- By research area: Breast Cancer (45), Lymphoma (44), Lung Cancer (41), Prostate Cancer (31), Melanoma (11), Pancreatic Cancer (10).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Durham
Basic details from each study's public record (the 30 most recently updated of 182). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Study site
- Duke University Medical Center
- Registry record
- NCT05696626 · updated
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Duke Cancer Center Durham
- Registry record
- NCT07488676 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT05564377 · updated
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- ALX Oncology Inc.
- Study site
- Duke Cancer Institute
- Registry record
- NCT07007559 · updated
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Duke Cancer Institute
- Registry record
- NCT03424005 · updated
The Vanguard Study: Testing a New Way to Screen for Cancer
- No phase
- Ages 45 to 75
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Durham VA Medical Center
- Registry record
- NCT06995898 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Lung cancer studies recruiting in Durham
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase 3
- Ages 18 to 100
- All sexes
- Sponsor
- Amgen
- Study site
- Duke University Medical Center Duke Cancer Center
- Registry record
- NCT05920356 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT04267848 · updated
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Duke University Medical Center
- Registry record
- NCT04886804 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Durham VA Medical Center
- Registry record
- NCT06096844 · updated
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Duke University Medical Center · Durham VA Medical Center
- Registry record
- NCT06498635 · updated
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Duke Cancer Institute
- Registry record
- NCT06646276 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Prostate cancer studies recruiting in Durham
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- VA Office of Research and Development
- Study site
- Durham VA Medical Center, Durham, NC
- Registry record
- NCT04038502 · updated
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- VA Office of Research and Development
- Study site
- Durham VA Medical Center, Durham, NC
- Registry record
- NCT05011383 · updated
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Phase 1/2
- Ages 18 and older
- Male participants
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Duke University Medical Center
- Registry record
- NCT07190300 · updated
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Amgen
- Study site
- Duke University Medical Center Duke Cancer Center
- Registry record
- NCT04221542 · updated
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
- Observational
- Ages 18 and older
- Male participants
- Sponsor
- Duke University
- Study site
- Duke University Medical Center
- Registry record
- NCT06141993 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Melanoma studies recruiting in Durham
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Duke University Medical Center
- Registry record
- NCT07068074 · updated
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Duke University
- Study site
- Duke University Medical Center
- Registry record
- NCT05077137 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Duke Health System
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Durham, NC on ClinicalTrials.gov.
Lymphoma studies recruiting in Durham
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study site
- Duke University Medical Center
- Registry record
- NCT06724237 · updated
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- Duke University
- Registry record
- NCT07221500 · updated
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Newave Pharmaceutical Inc
- Study site
- Duke Adult Blood and Marrow Clinic
- Registry record
- NCT07342478 · updated
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307)
- Registry record
- NCT07634471 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT05675410 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Duke University Medical Center
- Registry record
- NCT06337318 · updated
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- Nuvalent Inc.
- Study site
- Duke University Medical Center
- Registry record
- NCT05384626 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Durham, NC on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Durham
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Duke University Medical Center - Duke Cancer Center
- Registry record
- NCT07024615 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Ask about studies near Durham
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in North Carolina
All North Carolina locations
429 studies recruiting across 60 cities.
Chapel Hill
130 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections